[20250206] 온코크로스

의료AI 테마 상승 및 AI 신약개발업체 '리커전' 긍정적 임상 결과 발표 속 AI 플랫폼 ‘랩터 AI(RAPTOR AI)’ 보유 부각에 상한가

 

온코크로스(Oncocross)는 2015년에 설립된 대한민국의 인공지능(AI) 기반 신약 개발 전문기업입니다. 이 회사는 유전자 발현 데이터(전사체 데이터)를 AI로 분석하여 암, 희귀질환, 치매 등 난치성 질환에 대한 치료제를 개발합니다. 

주요 플랫폼으로는 RAPTOR AI(신약의 최적 적응증 발굴), ONCO-RAPTOR AI(항암제의 최적 암종 탐색), ONCOfind AI(원발부위불명암의 원발 부위 예측)가 있으며, 이를 통해 신약 개발 기간을 단축하고 성공률을 높이는 데 기여하고 있습니다[1][2][3].

 금일 상한가 이유
2025년 2월 6일, 온코크로스의 주가는 전일 대비 29.92% 상승하며 상한가(13,070원)를 기록했습니다. 주요 상승 요인은 다음과 같습니다:

1. AI 기반 신약 개발 기대감  
   온코크로스는 최근 AI를 활용한 신약 개발 및 적응증 확장 기술로 주목받고 있습니다. 특히, RAPTOR AI 플랫폼을 기반으로 국내외 제약사와 협업하며 신약 개발 경쟁력을 강화하고 있어 시장에서 긍정적인 평가를 받고 있습니다[1][4].

2. 차세대 성장 산업으로서의 주목  
   바이오 및 AI 기술이 융합된 신약 개발은 미래 성장 가능성이 큰 분야로 평가받고 있습니다. 온코크로스는 해당 분야에서 선도적인 위치를 차지하고 있어 투자자들의 관심이 집중되고 있습니다[3][6].

3. 지속적인 주가 상승세와 투자 심리 강화  
   온코크로스는 최근 상장 이후 지속적으로 상승세를 보이며 투자자들의 매수세가 강하게 유입되고 있습니다. 특히, 8거래일 연속 상승 흐름이 이어지며 금일 상한가에 도달한 것으로 보입니다[6][32].

이와 같은 요인들이 복합적으로 작용하며 온코크로스의 주가가 급등한 것으로 분석됩니다.

Citations:
[1] https://www.oncocross.com/mission
[2] https://www.biokorea.org/upload_BK/TECH/20210504120111_045789.pdf
[3] https://www.wanted.co.kr/company/13223
[4] https://www.ggilbo.com/news/articleView.html?idxno=1072400
[5] https://coincodex.com/stock/ONCO/price-prediction/
[6] https://www.cbci.co.kr/news/articleView.html?idxno=484175
[7] https://thevc.kr/oncocross
[8] https://www.koreatechdesk.com/company_profiles/oncocross/
[9] https://www.oncocross.com
[10] https://www.youtube.com/watch?v=EEH6UYsErd8
[11] https://www.bioworld.com/articles/715762-ai-cancer-firm-oncocross-debuts-with-60m-ipo-on-kosdaq?v=preview
[12] https://www.hankyung.com/article/202412269315a
[13] https://www.jobkorea.co.kr/recruit/co_read/c/oncocross
[14] https://www.oncocross.com/en
[15] https://www.youtube.com/watch?v=Q9qC6XrgAPQ
[16] https://www.jobplanet.co.kr/companies/383248/landing/%EC%98%A8%EC%BD%94%ED%81%AC%EB%A1%9C%EC%8A%A4
[17] https://www.oncocross.com/en/history
[18] https://www.innoforest.co.kr/company/CP00001700
[19] https://www.eugenefn.com/common/files/amail/20241129_B_jongsun.park_2270.pdf
[20] https://app.dealroom.co/companies/oncocross
[21] https://www.saramin.co.kr/zf_user/company-info/view-inner-salary/csn/ZWJxamdFY29WYkIyMWlDSXBoV1ZPdz09/company_nm/%EC%98%A8%EC%BD%94%ED%81%AC%EB%A1%9C%EC%8A%A4
[22] https://oncocross.irpage.co.kr
[23] https://www.ourcrowd.com/startup/oncocross
[24] http://comp.wisereport.co.kr/company/c1010001.aspx?cmp_cd=382150
[25] https://www.oncocross.com/overview
[26] https://www.bloomberg.com/tosv2.html?uuid=3b5beb09-be79-11ef-8b4c-91facfda1f5a&url=L3Byb2ZpbGUvY29tcGFueS8zODIxNTA6S1M%3D
[27] https://www.jobplanet.co.kr/companies/383248
[28] https://mkbn.mk.co.kr/news/stock/11197698
[29] http://www.newswell.co.kr/news/articleView.html?idxno=10261
[30] https://www.mk.co.kr/en/stock/11234577
[31] https://www.sedaily.com/NewsView/2DI63V7ZL0
[32] https://biz.chosun.com/stock/c-biz_bot/2025/02/06/UVFCSI3JFKMGOOE6HRE2SRULUM/
[33] https://oncodaily.com/insight/101093
[34] https://www.bloter.net/news/articleView.html?idxno=628443
[35] https://www.youtube.com/watch?v=mgpcCMPwBoM
[36] https://finance.yahoo.com/quote/ONCO/history/
[37] https://www.youtube.com/watch?v=knkTC_9veHg
[38] https://blog.naver.com/msql/223696746362?viewType=pc
[39] https://consent.yahoo.com/v2/collectConsent
[40] https://www.mk.co.kr/en/stock/11230899